Asia-Pacific Gastrointestinal Drugs Market Research Report Information: By Drug Class (Acid Neutralizers, Laxatives & Antidiarrheal, Anti-Emetics, Antiulcer), Type Of Disease (Esophagus Diseases, Stomach Diseases, Intestinal Diseases, Rectum Diseases) Forecast till 2030

1 Report Prologue

2 Introduction

2.1 Scope of Study 14

2.2 Research Objective 14

2.3 Assumptions & Limitations 14

2.3.1 Assumptions 14

2.3.2 Limitations 14

2.4 Market Structure 15

3 Research Methodology

3.1 Primary Research 18

3.2 Secondary Research 18

3.3 Market Size Estimation 18

3.3.1 Market Share analysis 19

3.4 Market Pricing Approach 20

4 Market Dynamics

4.1 Introduction 21

4.2 Drivers 22

4.2.1 Increasing prevalence of gastrointestinal diseases 22

4.2.2 Increasing investments and funding in the field of life science research 22

4.2.3 Increasing awareness among the people 23

4.2.4 Growing geriatric population 23

4.2.5 Changing reimbursement policies 23

4.3 Restraints 24

4.3.1 Presence of misbranded and spurious drugs 24

4.4 Opportunities 24

4.4.1 Development of new drugs 24

5 Market Factor Analysis

5.1 Porters Five forces Model 25

5.1.1 Bargaining Power Of Suppliers 26

5.1.2 Bargaining Power Of Buyers 26

5.1.3 Threat Of New Entrants 26

5.1.4 Threat Of Substitutes 26

5.1.5 Intensity Of Rivalry 26

5.2 Value Chain Analysis 27

5.2.1 R&D 27

5.2.2 Manufacturing 27

5.2.3 Distribution & Sales 28

5.2.4 Post-Sales Monitoring 28

5.3 Demand & Supply: Gap Analysis 28

5.4 Pricing Analysis 29

5.5 Investment Opportunity Analysis 29

5.6 Market Access Analysis 29

6 Asia Gastrointestinal Drugs Market, By Drug Class

6.1 Introduction 30

6.2 Acid Neutralizers 32

6.3 Laxatives and Antidiarrheal 33

6.4 Antiemetics 34

6.5 Antiulcer 34

7 Asia Gastrointestinal Drugs Market, By Type of Diseases

7.1 Introduction 35

7.2 Esophagus diseases 37

7.3 Stomach diseases 38

7.4 Intestinal diseases 38

7.5 Rectum Diseases 39

8 Asia Gastrointestinal Drugs Market, By Region

8.1 Introduction 40

8.2 Japan 42

Asia Gastrointestinal Drugs Market, By Drug Class

Asia Gastrointestinal Drugs Market, By Type of Diseases

8.3 China 44

Asia Gastrointestinal Drugs Market, By Drug Class

Asia Gastrointestinal Drugs Market, By Type of Diseases

8.4 India 46

Asia Gastrointestinal Drugs Market, By Drug Class

Asia Gastrointestinal Drugs Market, By Type of Diseases

8.5 Korea 48

Asia Gastrointestinal Drugs Market, By Drug Class

Asia Gastrointestinal Drugs Market, By Type of Diseases

8.6 Rest of Asia 51

Asia Gastrointestinal Drugs Market, By Drug Class

Asia Gastrointestinal Drugs Market, By Type of Diseases

8.6.1 Malaysia 54

Asia Gastrointestinal Drugs Market, By Drug Class

Asia Gastrointestinal Drugs Market, By Type of Diseases

8.6.2 Singapore 56

Asia Gastrointestinal Drugs Market, By Drug Class

Asia Gastrointestinal Drugs Market, By Type of Diseases

8.6.3 Indonesia 59

Asia Gastrointestinal Drugs Market, By Drug Class

Asia Gastrointestinal Drugs Market, By Type of Diseases

8.6.4 Thailand 61

Asia Gastrointestinal Drugs Market, By Drug Class

Asia Gastrointestinal Drugs Market, By Type of Diseases

8.6.5 Philippines 64

Asia Gastrointestinal Drugs Market, By Drug Class

Asia Gastrointestinal Drugs Market, By Type of Diseases

8.6.6 Vietnam 66

Asia Gastrointestinal Drugs Market, By Drug Class

Asia Gastrointestinal Drugs Market, By Type of Diseases

8.6.7 Others 68

Asia Gastrointestinal Drugs Market, By Drug Class

Asia Gastrointestinal Drugs Market, By Type of Diseases

9 Company Profile

9.1 Abbott 71

9.1.1 Company Overview 71

9.1.2 Product/Business Segment Overview 71

9.1.3 Financial Overview 72

9.1.4 Key Development 74

9.1.5 SWOT Analysis 75

9.2 Allergan Plc 76

9.2.1 Company Overview 76

9.2.2 Product/Business Segment Overview 76

9.2.3 Financial Overview 77

9.2.4 Key Developments 78

9.2.5 SWOT Analysis 78

9.3 AstraZeneca 79

9.3.1 Company Overview 79

9.3.2 Product/Business Segment Overview 79

9.3.3 Financial Overview 80

9.3.4 Key Development 81

9.3.5 SWOT Analysis 82

9.4 Eli Lilly Company 83

9.4.1 Company Overview 83

9.4.2 Product/Business Segment Overview 83

9.4.3 Financial Overview 83

9.4.4 Key Development 84

9.4.5 SWOT Analysis 85

9.5 F. Hoffmann-La Roche Ltd 86

9.5.1 Overview 86

9.5.2 Product/Business Segment Overview 86

9.5.3 Financial Overview 86

9.5.4 Key Development 87

9.5.5 SWOT Analysis 88

9.6 GlaxoSmithKline plc. 89

9.6.1 Company Overview 89

9.6.2 Product/ Business segment overview 89

9.6.3 Financial Overview 89

9.6.4 Key Development 91

9.6.5 SWOT Analysis 92

9.7 Pfizer Inc 93

9.7.1 Overview 93

9.7.2 Product/Business Segment Overview 93

9.7.3 Financial Overview 93

9.7.4 Key Development 94

9.7.5 SWOT Analysis 95

9.8 Valeant Pharmaceuticals 96

9.8.1 Company Overview 96

9.8.2 Product overview 96

9.8.3 Financial Overview 97

9.8.4 Key Development 98

9.8.5 SWOT Analysis 99

10 Company Landscape

10.1 Introduction 100

10.2 Company Share Analysis 100

10.3 Key Developments 101

11 Conclusion

11.1 Key Findings 103

11.1.1 CEO’s Viewpoint 103

11.1.2 Unmet Needs 103

11.1.3 Key Companies to Watch 103

11.1.4 Prediction of Asia Gastrointestinal Drugs Industry 103

12 Appendix

12.1 Discussion Blue Print 104

12.2 References 105

13 List of Tables

TABLE 1 PRIMARY INTERVIEWS 19

TABLE 2 ASIA GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 31

TABLE 3 ACID NEUTRALIZERS GASTROINTESTINAL DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION) 32

TABLE 4 LAXATIVE AND ANTIDIARRHEAL GASTROINTESTINAL DRUGS MARKET, BY REGION,

2020-2027 (USD MILLION) 33

TABLE 5 ANTIEMETIC GASTROINTESTINAL DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION) 34

TABLE 6 ANTIULCER GASTROINTESTINAL DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION) 34

TABLE 7 ASIA GASTROINTESTINAL DRUGS MARKET, BY TYPE OF DISEASES, 2020-2027 (USD MILLION) 36

TABLE 8 ESOPHAGUS DISEASES GASTROINTESTINAL DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION) 37

TABLE 9 STOMACH DISEASES GASTROINTESTINAL DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION) 38

TABLE 10 INTESTINAL DISEASES GASTROINTESTINAL DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION) 38

TABLE 11 RECTUM DISEASES GASTROINTESTINAL DRUGS MARKET, BY REGION , 2020-2027 (USD MILLION) 39

TABLE 12 ASIA GASTROINTESTINAL DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION) 41

TABLE 13 JAPAN GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS , 2020-2027 (USD MILLION) 42

TABLE 14 JAPAN GASTROINTESTINAL DRUGS MARKET, BY TYPE OF DISEASES , 2020-2027 (USD MILLION) 43

TABLE 15 CHINA GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS , 2020-2027 (USD MILLION) 44

TABLE 16 CHINA GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2020-2027 (USD MILLION) 45

TABLE 17 INDIA GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS , 2020-2027 (USD MILLION) 46

TABLE 18 INDIA GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2020-2027 (USD MILLION) 47

TABLE 19 KOREA GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS , 2020-2027 (USD MILLION) 48

TABLE 20 KOREA GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2020-2027 (USD MILLION) 50

TABLE 21 REST OF ASIA GASTROINTESTINAL DRUGS MARKET, BY REGION , 2020-2027 (USD MILLION) 51

TABLE 22 REST OF ASIA GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS , 2020-2027 (USD MILLION) 52

TABLE 23 REST OF ASIA GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2020-2027 (USD MILLION) 53

TABLE 24 MALAYSIA GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS , 2020-2027 (USD MILLION) 54

TABLE 25 MALAYSIA GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2020-2027 (USD MILLION) 55

TABLE 26 SINGAPORE GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS , 2020-2027 (USD MILLION) 56

TABLE 27 SINGAPORE GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2020-2027 (USD MILLION) 57

TABLE 28 INDONESIA GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS , 2020-2027 (USD MILLION) 59

TABLE 29 INDONESIA GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2020-2027 (USD MILLION) 60

TABLE 30 THAILAND GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS , 2020-2027 (USD MILLION) 61

TABLE 31 THAILAND GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2020-2027 (USD MILLION) 62

TABLE 32 PHILIPPINES GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS , 2020-2027 (USD MILLION) 64

TABLE 33 PHILIPPINES GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2020-2027 (USD MILLION) 65

TABLE 34 VIETNAM GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS , 2020-2027 (USD MILLION) 66

TABLE 35 VIETNAM GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2020-2027 (USD MILLION) 67

TABLE 36 OTHERS GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS , 2020-2027 (USD MILLION) 68

TABLE 37 OTHERS GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2020-2027 (USD MILLION) 70

TABLE 38 ABBOTT: KEY DEVELOPMENT 74

TABLE 39 ALLERGAN: KEY DEVELOPMENT 78

TABLE 40 ASTRAZENECA: KEY DEVELOPMENT 81

TABLE 41 ELI LILLY COMPANY : KEY DEVELOPMENT 84

TABLE 42 F. HOFFMANN-LA ROCHE AG: KEY DEVELOPMENT 87

TABLE 43 GLAXOSMITHKLINE: KEY DEVELOPMENT 91

TABLE 44 VALEANT PHARMACEUTICALS: KEY DEVELOPMENT 98

14 List of Figures

FIGURE 1 ASIA GASTROINTESTINAL DRUG MARKET SHARE, BY DRUG TYPE, 2020 (%) 11

FIGURE 2 ASIA GASTROINTESTINAL DRUG MARKET SHARE, BY TYPE OF DISEASES, 2020 (%) 12

FIGURE 3 ASIA GASTROINTESTINAL DRUG MARKET SHARE, BY REGION, 2020 (%) 12

FIGURE 4 ASIA GASTROINTESTINAL DRUGS MARKET: MARKET STRUCTURE 15

FIGURE 5 RESEARCH PROCESS 16

FIGURE 6 DRIVERS & RESTRAINTS IMPACT ANALYSIS OF ASIA GASTROINTESTINAL DRUG MARKET 21

FIGURE 7 PORTERS FIVE FORCES MODEL 25

FIGURE 8 VALUE CHAIN: GASTROINTESTINAL DRUGS 27

FIGURE 9 ASIA GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS 2020 & 2027 (USD MILLION) 30

FIGURE 10 ASIA GASTROINTESTINAL DRUGS MARKET, BY TYPE OF DISEASES 2020 & 2027 (USD MILLION) 36

FIGURE 11 ASIA GASTROINTESTINAL DRUGS MARKET, BY REGION 2020 & 2027 (USD MILLION) 41

FIGURE 12 ABBOTT: RECENT FINANCIALS (USD MILLION) 72

FIGURE 13 ABBOTT: GEOGRAPHICAL MIX, 2020 (%) 73

FIGURE 14 ABBOTT: SEGMENTAL MIX, 2020 (%) 73

FIGURE 15 ABBOTT LABORATORIES: SWOT ANALYSIS 75

FIGURE 16 ALLERGAN REVENUE 2020-2020 77

FIGURE 17 ALLERGAN BUSINESS AND GEOGRAPHIC REVENUE MIX 77

FIGURE 18 ALLERGAN: SWOT ANALYSIS 78

FIGURE 19 ASTRAZENECA: RECENT FINANCIAL 80

FIGURE 20 ASTRAZENECA: GEOGRAPHICAL MIX 80

FIGURE 21 ASTRAZENECA: OPERATING SEGMENTS MIX 81

FIGURE 22 ASTRAZENECA: SWOT ANALYSIS 82

FIGURE 23 ELI LILLY COMPANY : RECENT FINANCIAL 83

FIGURE 24 ELI LILLY COMPANY : BUSINESS REVENUE MIX (2020) 84

FIGURE 25 ELI LILLY COMPANY : GEOGRAPHIC REVENUE MIX 84

FIGURE 26 ELI LILLY COMPANY : SWOT ANALYSIS 85

FIGURE 27 F. HOFFMANN-LA ROCHE AG: RECENT FINANCIAL (SALES) 86

FIGURE 28 F. HOFFMANN-LA ROCHE AG: SEGMENTAL MIX (%) 87

FIGURE 29 F. HOFFMANN-LA ROCHE AG: GEOGRPAHICAL MIX 87

FIGURE 30 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS 88

FIGURE 31 GLOAXOSMITHKLINE: RECENT FINANCIAL 89

FIGURE 32 GLAXOSMITHKLINE: OPERATING SEGMENT MIX 90

FIGURE 33 GLAXOSMITHKLINE: GEOGRAPHICAL MIX 90

FIGURE 34 GLAXOSMITHKLINE: SWOT ANALYSIS 92

FIGURE 35 PFIZER FINANCIAL DATA: REVENUE AND R&D 93

FIGURE 36 PFIZER FINANCIAL DATA SEGMENTAL MIX 94

FIGURE 37 PFIZER FINANCIAL DATA GEOGRAPHICAL MIX 94

FIGURE 38 PFIZER: SWOT ANALYSIS 95

FIGURE 39 VALEANT PHARMACEUTICALS REVENUE 97

FIGURE 40 VALEANT PHARMACEUTICALS SEGMENTAL REVENUE 97

FIGURE 41 VALEANT PHARMACEUTICALS GEOGRAPHICAL REVENUE 98

FIGURE 42 VALEANT PHARMACEUTICALS: SWOT ANALYSIS 99

FIGURE 43 ASIA GASTROINTESTINAL DRUGS COMPANY SHARE ANALYSIS, 2020 (%) 100